COVID-19 UPDATE

Two days ago, EMA notified the start of a rolling review of data on the monoclonal antibody regdanvimab (Celltrion) for the treatment of COVID-19.

Two days ago, EMA notified the start of a rolling review of data on the monoclonal antibody regdanvimab (Celltrion) for the treatment of COVID-19.
February 26, 2021

Two days ago, EMA notified the start of a rolling review of data on the monoclonal antibody regdanvimab (Celltrion) for the treatment of COVID-19. These are great news, as now there are a total of 5 products being evaluated by EMA (3 vaccines and 2 treatments) which could be placed on the market during the following months, depending on the results of the evaluation.

The development of new tools to treat COVID-19 brings renewed hopes to fight against the pandemic. At Asphalion we are actively aiding in the development of vaccines and treatments for COVID-19, bringing our best to help all developers get their products ready to be authorized.

For further information you can contact us at: info@asphalion.com

Search News & Events

  • Filter by category

Share

Related news and events

People Talks | Meet our Exceptional Team!

At our “People Talks” we feature some of the amazing people who make up our Asphalion family, so you can get to know them better and understand how their contributions shape our company’s success.

ASPHATEAM | TEAM BUILDING

At our anual team building last Friday, we engaged in building Solidarity Bikes, in line with our CSR objectives. The goal was getting bicycles assembled

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting